Search results
Zumutor is a leading Immuno-Oncology company in the space of targeted NK cell therapeutics. Our proprietary Human Antibody platform INABLR ™ is the genesis to our wholly owned, first-in-class therapeutic antibodies which target innate immunity and regulate the tumor micro environment.
Zumutor Biologics | 6,051 followers on LinkedIn. A leading Immuno Oncology company in the space of NK cell therapeutics | At Zumutor, we are on a mission to develop novel novel immuno...
Jun 12, 2024 · BOSTON and BANGALORE, India, June 12, 2024 /PRNewswire/ -- Zumutor Biologics Inc. "Zumutor", a Boston -based clinical stage Oncology Company developing first-in-class monoclonal antibody...
Apr 8, 2021 · Zumutor has developed multiple expression platforms which lead to improvement of antibody dependent cellular cytotoxicity of therapeutic antibodies. The ADCC Improvement Platform and methods of development are unique and we have filed patent applications to secure global IP rights.
Aug 11, 2023 · Zumutor is a novel immuno therapeutics company driving transformational change by harnessing the power of NK cells in modulating the Tumor Micro Environment (TME).
Jun 12, 2024 · Zumutor Biologics Inc announces collaboration with Enzene Biosciences for it’s INABLR™ Antibody discovery platform. Click here to read the Press Release. Oct 2023. Meet us at ESMO 2023 in Madrid. ESMO CONGRESS 2023: Biomarkers for novel NK checkpoint inhibitor anti LLT1 antibody, ZM008–patient transcriptome analysis. Click here to Register.
Jun 12, 2024 · Zumutor is a novel immuno therapeutics company driving transformational change by harnessing the power of NK cells in modulating the Tumor Micro Environment (TME).
Aug 14, 2023 · Zumutor Biologics Inc announced that the FDA granted the company's Investigational New Drug (IND) application for the novel drug ZM008 to initiate a Phase 1, first-in-human, clinical study for the treatment of multiple solid cancers.
Jun 12, 2024 · Understanding the Trial Design. The ZM008-001 trial is an open-label, first-in-human, multicenter, Phase 1 dose escalation trial of ZM008 administered alone or combined with Pembrolizumab. The...
Aug 14, 2023 · Boston and Bengaluru-based biopharmaceutical company, Zumutor Biologics has received an approval from the US Food and Drug Administration (FDA) to initiate phase 1 human trials for its experimental drug ZM008 that targets multiple solid cancers.
